Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-10-31
2010-06-15
Mondesi, Robert B (Department: 1645)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S069100, C424S263100, C536S023100, C536S023700, C530S300000, C530S350000
Reexamination Certificate
active
07736873
ABSTRACT:
The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain ofChlamydia, specificallyC. pneumoniae, employing a vector containing a nucleotide sequence encoding a 98 kDa outer membrane protein of a strain ofChlamydia pneumoniaeand a promoter to effect expression of the 98 kDa outer membrane protein gene in the host. Modifications are possible within the scope of this invention.
REFERENCES:
patent: 5525463 (1996-06-01), Zolg
patent: 5629167 (1997-05-01), Ratti
patent: 6521745 (2003-02-01), Murdin et al.
patent: 6559294 (2003-05-01), Griffais et al.
patent: 6693087 (2004-02-01), Murdin et al.
patent: 6808713 (2004-10-01), Murdin et al.
patent: 6822071 (2004-11-01), Stephens et al.
patent: 7019125 (2006-03-01), Murdin et al.
patent: 7070792 (2006-07-01), Murdin et al.
patent: 7081245 (2006-07-01), Murdin et al.
patent: 2002/0082402 (2002-06-01), Murdin et al.
patent: 2002/0094965 (2002-07-01), Murdin et al.
patent: 2002/0099188 (2002-07-01), Murdin et al.
patent: 2002/0132994 (2002-09-01), Murdin et al.
patent: 2003/0100706 (2003-05-01), Murdin et al.
patent: 2004/0254130 (2004-12-01), Murdin et al.
patent: 319944 (1988-07-01), None
patent: 592894 (1993-01-01), None
patent: 430930 (1996-12-01), None
patent: 0784059 (1997-07-01), None
patent: WO 98/02546 (1998-01-01), None
patent: WO 98/58953 (1998-12-01), None
patent: WO 99/27105 (1999-06-01), None
patent: WO 99/28475 (1999-06-01), None
patent: WO 00/24765 (2000-05-01), None
patent: WO00/27994 (2000-05-01), None
patent: WO 00/34483 (2000-06-01), None
patent: WO 00/37494 (2000-06-01), None
patent: WO 00/46359 (2000-08-01), None
patent: WO 00/66739 (2000-11-01), None
patent: WO 01/21804 (2001-03-01), None
patent: WO 01/21811 (2001-03-01), None
patent: WO 01/40474 (2001-06-01), None
patent: WO 01/46224 (2001-06-01), None
patent: WO 01/81379 (2001-11-01), None
patent: WO 01/85972 (2001-11-01), None
patent: WO 02/02606 (2002-01-01), None
patent: WO 02/08267 (2002-01-01), None
Lederman et al (Molecular Immunology 28:1171-1181, 1991).
Li et al (Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980).
Houghten et al. (Vaccines, 1986, Edited by Fred Brown: Cold Spring Harbor Laboratory).
Holmes, Exp. Opin.Invest. Drugs, 2001, 10(3):511-519).
Greenspan et al (Nature Biotechnology, 1999, 7:936-937).
U.S. Appl. No. 09/857,128, filed Sep. 20, 2001, Murdin et al.
U.S. Appl. No. 09/868,987, filed Dec. 23, 1999, Murdin et al.
U.S. Appl. No. 09/471,194, filed Dec. 23, 1999, Murdin et al.
U.S. Appl. No. 09/522,606, filed Mar. 10, 2000, Murdin et al.
U.S. Appl. No. 09/609,243, filed Jun. 30, 2000, Murdin et al.
U.S. Appl. No. 09/662,813, filed Sep. 15, 2000, Murdin et al.
U.S. Appl. No. 09/663,362, filed Sep. 15, 2000, Murdin et al.
U.S. Appl. No. 09/663,360, filed Sep. 15, 2000, Murdin et al.
U.S. Appl. No. 09/663,361, filed Sep. 15, 2000, Murdin et al.
U.S. Appl. No. 09/662,814, filed Sep. 15, 2000, Murdin et al.
U.S. Appl. No. 09/662,812, filed Sep. 15, 2000, Murdin et al.
U.S. Appl. No. 09/709,473, filed Nov. 13, 2000, Murdin et al.
U.S. Appl. No. 09/709,474, filed Nov. 13, 2000, Murdin et al.
U.S. Appl. No. 09/709,384, filed Nov. 13, 2000, Murdin et al.
U.S. Appl. No. 09/747,349, filed Dec. 22, 2000, Murdin et al.
U.S. Appl. No. 09/523,647, filed Mar. 10, 2000, Murdin et al.
Allegra et al.; “Acute Exacerbations of Asthma in Adults: role ofChlamydia pneumoniaeInfection”; European Respiratory Journal; vol. 7, No. 12; Dec. 1994; pp. 2165-2168.
Arnon et al. FASEB J. Nov. 1992; 6(14): 3265-74.
Attwood et al., Science (2000) 290:471-473.
Ausubel et al.; “Current Protocols in Molecular Biology”; John Wiley & Sons Inc.; vol. 1; 1994; 15 sheets.
Bachmaier et al.; “ChlamydiaInfections and Heart Disease Linked Through Antigenic Minicry”; Science; vol. 283; Feb. 26, 1999; pp. 1335-1339.
Bjornsson et al.; “Serology ofChlamydiain relation to Asthma and Bronchial Hyperresponsiveness”; Scand Journal of Infection Diseases; vol. 28, No. 1; 1996; pp. 63-69.
Boselgo et al., Vaccines and Immunotherapy (1991) Chap. 17: Gonorrhea Vaccines, pp. 211-223.
Bowie et al (Science, 1990, 257:1306-1310).
Burgess et al., The Journal of Cell Biology, 111:2129-2138, 1990.
Cagnon et al.; “A New Family of Sugar-Inducible Expression Vectors forEscherichia coli”; Protein Engineering; vol. 4, No. 7; 1991; pp. 843-847.
Campbell et al.; “Serological Response toChlamydia pneumoniaeInfection”; Journal of Clinical Microbiology; vol. 28, No. 6; Jun. 1990; pp. 1261-1264.
Campbell et al.; “Detection ofChlamydia pneumoniaeTWAR in Human Coronary Atherectomy Tissues”; The Journal of Infectious Diseases; vol. 172, No. 2; Aug. 1995; pp. 585-588.
Campbell et al.; “Structural and Antigenic Analysis ofChlamydia pneumoniae”; Infection and Immunity; vol. 58, No. 1; Jan. 1990; pp. 93-97.
Campos et al. ; “AChlamydialmajor Outer Membrane Protein Extract as a Trachoma Vaccine Candidate”; Investigation of Ophthalmology and Visual Science; vol. 36, No. 8; Jul. 1995; pp. 1477-1491.
Casey & Davidson; Nucleic Acids Research; vol. 4, No. 5; 1977; pp. 1539-1553.
Cotter et al.; Protective Efficacy of Major Outer Membrane Protein-Specific Immunoglobulin A (IgA) and IgG Monoclonal Antibodies in a Murine Model ofChlamydia trachomatisGenital Tract Infection; Infection and Immunity; vol. 63, No. 12; Dec. 1995; pp. 4704-4714.
Chiu et al.; “Chlamydia pneumoniae, Cytomegalovirus, and Herpes Simplex Virus in Atherosclerosis of the Carotid Artery”; Circulation; vol. 96, No. 7; Oct. 7, 1997; pp. 2144-2148.
Current Protocols in Immunology, 1997 unit 9.7.5.
Davis et al.; “A Manual for Genetic Engineering: Advanced Bacterial Genetics”; Cold Spring Harbor Laboratory Press; 1980; pp. 174-176. cited by other.
Dion et al.; “Virus Envelope-Based Peptide Vaccines Against Virus-Induced Mammary Tumors”; Virology; vol. 179, No. 1; Nov. 1990; pp. 474-477.
Ellis, Vaccines: New Technologies for Making vaccines (1988), pp. 568-574.
Fong et al.; “Rabbit Model forChlamydia pneumoniaeInfection”; Journal of Clinical Microbiology; vol. 15, No. 1; Jan. 1997; pp. 48-52.
Gaydos et al.; “Similarity ofChlamydia pneumoniaeStrains in the Variable Domain IV Region of the Major Outer Membrane Protein Gene”; Infection and Immunity; vol. 60, No. 12; Dec. 1992; pp. 5319;5323.
Grayston et al.; “Evidence thatChlamydia pneumoniaeCauses Pneumonia and Bronchitis”; The Journal of Infectious Diseases; vol. 168, No. 5; Nov. 1995; pp. 1231-1235.
Grayston et al.; “A New Respiratory Tract Pathogen:Chlamydia pneumoniaeStrain TWAR”; The Journal of Infectious Diseases; vol. 161, No. 4; Apr. 1990; pp. 618-625.
Hahn; “Treatment ofChlamydia pneumoniaeInfection in Adult Asthma: A Before-After Trial”; J. Fam. Pract. vol. 41, No. 4; Oct. 1995; pp. 345-351.
Hahn et al.; “Association ofChlamydia pneumoniae(Strain TWAR) Infection With Wheezing, Asthmatic Bronchitis, and Adult-Onset Asthma”; The Journal of the American Medical Association; vol. 266, No. 2; Jul. 10, 1991; pp. 225-230.
Hahn et al.; “Evidence forChlamydia pneumoniaeInfection in Steroid-Dependent Asthma”; Ann Allergy Asthma Immunology; vol. 80, No. 1, Jan. 1998; pp. 45-49.
Hahn et al.; “Association ofChlamydia pneumoniaeIgA Antibodies With Recently Symptomatic Asthma”; Epidemiology Infection; vol. 117, No. 3; Dec. 1996; pp. 513-517.
Herbert et al The Dictionary of Immunology, Academic Press, 3rd Edition, London, 1985, pp. 58-59.
Holmes Exp. Opin. Invest. Drugs, 2001, 10(3):511-519.
Hughes et al.; “Synthetic Peptides Representing Epitopes of Outer Membrane Protein F ofPseudomonas aeruginosaThat Elicit Antibodies Reactive With Whole Cells of Heterologous Immunotype Strains ofP. aeruginosa”; Infection and Immunity; vol. 60, No. 9, Sep. 1992; pp. 3497-3503.
Igietseme et al.; “Resolution of MurineChlamydialGenital Infection
Dunn Pamela
Murdin Andrew D.
Oomen Raymond P.
Wang Joe
Baskar Padma V
Mondesi Robert B
Sanofi Pasteur Limited
LandOfFree
Chlamydia polypeptides and corresponding DNA fragments and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chlamydia polypeptides and corresponding DNA fragments and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chlamydia polypeptides and corresponding DNA fragments and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4247187